Atoltivimab/maftivimab/odesivimab

Atoltivimab/maftivimab/odesivimab
Combination of
Atoltivimab	Monoclonal antibody
Maftivimab	Monoclonal antibody
Odesivimab	Monoclonal antibody
Clinical data
Trade names	Inmazeb
Other names	REGN-EB3
AHFS/Drugs.com	Monograph
License data	US DailyMed: Inmazeb;
Routes of; administration	Intravenous
ATC code	None;
Legal status
Legal status	US: ℞-only;
Identifiers
CAS Number	2500649-90-9;
KEGG	D11922;

Atoltivimab/maftivimab/odesivimab, sold under the brand name Inmazeb, is a fixed-dose combination of three monoclonal antibodies for the treatment of Zaire ebolavirus (Ebola virus). It contains atoltivimab, maftivimab, and odesivimab-ebgn and was developed by Regeneron Pharmaceuticals.

The most common side effects include fever, chills, tachycardia (fast heart rate), tachypnea (fast breathing), and vomiting; however, these are also common symptoms of Ebola virus infection.

Atoltivimab/maftivimab/odesivimab is the first FDA-approved treatment for Zaire ebolavirus. Atoltivimab/maftivimab/odesivimab was approved for medical use in the United States in October 2020. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. It is on the World Health Organization's List of Essential Medicines.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.